- Home
- FFIE vs VERU Comparison
FFIE vs VERU Comparison
Compare FFIE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIE
- VERU
- Stock Information
- Founded
- FFIE 2014
- VERU 1971
- Country
- FFIE United States
- VERU United States
- Employees
- FFIE N/A
- VERU N/A
- Industry
- FFIE Auto Manufacturing
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- FFIE Consumer Discretionary
- VERU Health Care
- Exchange
- FFIE Nasdaq
- VERU Nasdaq
- Market Cap
- FFIE 97.5M
- VERU 108.8M
- IPO Year
- FFIE N/A
- VERU 1990
- Fundamental
- Price
- FFIE $1.60
- VERU $0.57
- Analyst Decision
- FFIE
- VERU Strong Buy
- Analyst Count
- FFIE 0
- VERU 4
- Target Price
- FFIE N/A
- VERU $4.00
- AVG Volume (30 Days)
- FFIE 11.5M
- VERU 6.2M
- Earning Date
- FFIE 11-06-2024
- VERU 02-13-2025
- Dividend Yield
- FFIE N/A
- VERU N/A
- EPS Growth
- FFIE N/A
- VERU N/A
- EPS
- FFIE N/A
- VERU N/A
- Revenue
- FFIE $537,000.00
- VERU $16,886,419.00
- Revenue This Year
- FFIE $10,958.67
- VERU N/A
- Revenue Next Year
- FFIE $617.65
- VERU N/A
- P/E Ratio
- FFIE N/A
- VERU N/A
- Revenue Growth
- FFIE N/A
- VERU 22.46
- 52 Week Low
- FFIE $0.99
- VERU $0.49
- 52 Week High
- FFIE $156.00
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- FFIE 51.72
- VERU 44.48
- Support Level
- FFIE $1.49
- VERU $0.49
- Resistance Level
- FFIE $1.86
- VERU $0.56
- Average True Range (ATR)
- FFIE 0.18
- VERU 0.05
- MACD
- FFIE 0.04
- VERU 0.00
- Stochastic Oscillator
- FFIE 46.84
- VERU 63.62
About FFIE Faraday Future Intelligent Electric Inc.
Faraday Future Intelligent Electric Inc is a global shared intelligent mobility ecosystem. It is poised to break the boundaries between the Internet, IT, creative, and auto industries with product and service offerings that integrate new energy, AI, Internet, and sharing models.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.